慢性丙型肝炎患者外周血单个核细胞丙型肝炎病毒感染研究

目的 以分子生物学、免疫学有电镜等技术对慢性丙型肝炎患者ＰＢＭＣｓ进行综合检测,以证实其受ＨＣＶ感染,并试图在电镜下发现和证实感染细胞内ＨＣＶ颗粒。方法 对逆转录聚合酶链反应（ＲＴ－ＰＣＲ）和免疫组织化学等技术分别检测患者ＰＢＭＣｓ内的ＨＣＶ ＲＮＡ和ＨＣＶＡｇ,以常规和免疫电镜技术观察研究感染细胞内ＨＣＶ的形态、定位和超微结构。结果 ＨＣＶ ＲＮＡ阳性检出率为７７．２％（１７／２２）,ＨＣＶＡｇ     

慢性丙型肝炎患者外周血单个核细胞中HCV RNA和NS5抗原的检测

目的 研究丙型肝炎病毒（ＨＣＶ）感染外周血个核细胞（ＰＢＭＣ）的情况及其意义。方法 运用非核素原位杂交法（ＮＩＳＨ）和抗生蛋白链菌素－生物素法（ＳＡＢＣ）分别检测２０例慢性丙型肝炎患者ＰＢＭＣ中的ＨＣＶ ＲＮＡ和ＮＳ５抗原。结果 ２０例患者中有８例（４０％）,ＰＢＭＣ中ＨＣＶ ＲＮＡ呈阳性,其中６例（３０％）ＰＢＭＣ中ＮＳ５抗原同时呈阳性。ＨＣＶＲＮＡ主要分布于胞浆中,而ＮＳ５抗原还可以出现在胞膜     

丙型肝炎患者血清和外周血单个核细胞中HCV RNA检测及意义

采用套式PCR检测38例急性丙型肝炎和36例慢性丙型肝炎患者血清和外周血单个核细胞(PBMC)中HCV RNA。结果显示74例丙型肝炎患者血清HCV RNA阳性68例,PBMC阳性44例;急性丙型肝炎患者PBMC中HCV RNA阳性15例(39.5％),慢性丙型肝炎患者PBMC中阳性29例(80.5％);3例血清HCV RNA阴性,而PBMC中HCV RNA阳性;8例患者血清抗-HCV阴性,而血清HCV RNA阳性。结果显示,在部分丙型肝炎患者的PBMC中存在HCV RNA,慢性丙型肝炎患者PMBC中HCV RNA检出率显著高于急性丙型肝炎患者(P<0.01)。提示PBMC可能为HCV肝外贮存和复制场所,PBMC中的HCV感染在丙型肝炎慢性化和慢性肝损害中可能起一定作用,血清HCV RNA检测可能有助于抗-HCV阴性丙型肝炎的诊断。     

丙型肝炎患者外周血单个核细胞对特异性HCV抗原增殖反应

丙型肝炎病毒（ＨＣＶ）的发病机制和机体对ＨＣＶ的免疫应答目前尚不十分清楚。为此,我们研究了丙型肝炎（ＨＣ）患者外周血单个核细胞（ＰＢＭＣ）对ＨＣＶ特异性抗原的增殖反应,从细胞免疫的角度分析机体抗ＨＣＶ免疫功能及其与临床预后的相关性。材料与方法一、病例...     

丙型肝炎病人骨髓单个核细胞中HCV—RNA的检测及其意义

采用逆转录套式ＰＣＲ法，对２０例慢丙型肝炎患者骨髓单个核细胞中ＨＣＶ－ＲＮＡ进行了检测，在２０例血清抗ＨＣＶ阳性及ＨＣＶ－ＲＮＡ阳性的患者中，１６例骨髓单个核细胞ＨＣＶ－ＲＮＡ呈阳性反应，４例为阴性反应，阳性率达８０％。结果表明，骨髓单个核细胞中存在ＨＣＶ，提示骨髓可甬ＨＣＶ肝外又一感染复制及贮存的民。并对肝外ＨＣＶ感染、复制与内肝慢性化的致病关系，以及临床治疗进行了讨论。     

丙型肝炎患者血清和外周血单个核细胞中HCV RNA检测及意义

目的 了解丙肝患者血清和外周血单个核细胞（ＰＢＭＣ）中ＨＣＶＲＮＡ存在情况及有其临床意义，方法 应用套式ＰＣＲ检测４６例急性丙型肝炎（丙型肝炎以下简称丙肝）和４２例慢性丙型肝炎患者血清和ＰＢＭＣ中ＨＣＶＲＮＡ。结果 慢性丙型肝炎患者ＰＢＭＣ中ＨＣＶＲＮＡ检出率显著高于急性丙型患者（Ｐ〈０．００１），急，慢性丙型肝患者血清和慢性丙肝患者ＰＢＭＣ中ＨＣＶ ＲＮＡ检出率显著高于ＡＬＴ正常的抗－ＨＣＶ阳性     

献血员100例血清和外周血单个核细胞中丙型肝炎病毒RNA的检测

为了解丙型肝炎病毒抗体(抗ＨＣＶ)阴性献血员中隐匿性ＨＣＶ感染的状况,我们采用逆转录套式聚合酶链反应(ＲＴＮｅｓｔｅｄＰＣＲ)对100例献血员血清和外周血单个核细胞(ＰＢＭＣ)中ＨＣＶＲＮＡ进行了检测,现将结果报告如下。材料和方法一、检测对象随机选择血清抗ＨＣＶ阴性,血清丙氨酸氨基转移酶(ＡＬＴ)正常的献血员100例。其中,男58例,女42例,取血清-20℃冻存待检。二、ＰＢＭＣ分离及ＨＣＶＲＮＡ提取取肝素抗凝血5ｍｌ,立即用淋巴细胞分离液分离出ＰＢＭＣ,用Ｈａｎｋ液漂洗ＰＢＭＣ5次后,冻存于-70℃备检。ＰＢＭＣ和血清中ＨＣＶ…     

慢性丙型肝炎患者外周血单个核细胞HCV RNA检测及其与机体免疫功能的相关性研究

目的观察慢性丙型肝炎患者外周血单个核细胞(PBMC)HCVRNA含量及其对T淋巴细胞亚群的影响,以探讨HCV感染者PBMC中HCVRNA水平及其与机体免疫功能的关系。方法采用荧光定量PCR(FQPCR)技术对128例丙型肝炎患者血清、外周血单个核细胞的HCVRNA含量进行了检测,同时检测CD3+、CD4+、CD8+、CD4+/CD8+。结果PBMC内HCVRNA阳性组与HCVRNA阴性组比较,前者CD3+、CD4+水平降低、CD8+水平增高,CD4+/CD8+比值下降大于后者,差异有显著性(P<0.05)。结论丙型肝炎病毒侵染PBMC后可加重患者的细胞免疫功能紊乱。     

丙型肝炎患者外周血单个核细胞内HCV感染与干扰素疗效反应

干扰素(IFN)已广泛用于丙型肝炎的治疗,但持续应答者仅占少数,短期应答者居多,且停止治疗后易复发,无应答者占相当比例.     

原位杂交法检测外周血单个核细胞中HCV RNA

目的比较慢性丙型肝炎患者用干扰素治疗前以及治疗后３个月ＰＢＭＣ中ＨＣＶＲＮＡ。方法应用地高辛素标记ＨＣＶＲＮＡ正链及负链探针，建立原位杂交方法检测外周血单个核细胞（ＰＭＢＣ）中的ＨＣＶＲＮＡ。结果治疗前１９例患者正链ＨＣＶＲＮＡ阳性，８例负链ＨＣＶＲＮＡ阳性，用正链探针杂交在较多的细胞中出现杂交信号，负链探针杂交仅在少数细胞中出现杂交信号，ＨＣＶＲＮＡ在ＰＢＭＣ胞浆中呈均质性分布。用干扰素治疗结束后３个月２０例患者中９例ＨＣＶＲＮＡ转阴性，近期治愈率４５％。结论原位杂交技术的敏感性及特异性较高，且重复性较好，是研究ＨＣＶＲＮＡ在组织中定位分布和病毒复制场所一种切实可行的方法     

乙型肝炎患者外周血单个核细胞端粒酶活性的研究

目的 了解乙型肝炎患者外周血单个核细胞（PBMC）端粒酶活性的表达情况。方法 通过扩增端粒重复序列（TRAP）及光度酶联免疫法，分别检测健康人及各类乙型肝炎患者PBMC的端粒酶水平。结果 各组患者PBMC在植物血凝素（PHA）刺激前均有端粒酶活性的表达，以急性型肝炎组最高，重型肝炎组最低，二者差别具有显著性（P〈0．001）。PHA刺激后与刺激前比较各组端粒酶活性均有显著性升高（P〈0．001），刺激后的端粒酶水平以重型肝炎组为最低，与其他三组比较差别具有显著性（P〈0．05）。慢性重型乙型肝炎经胸腺五肽（TP5）治疗后端粒酶活性显著增高（P〈0．05）。结论 HBV急性感染期PBMC的端粒酶水平升高；慢性感染期PBMC的端粒酶水平在体内被抑制。TP5具有免疫调节作用，能使过低的端粒酶水平趋向于正常。     

慢性乙型肝炎患者外周血单个核细胞及肝组织中HBV cccDNA定量检测

目的优化HBV共价闭合环状DNA(cccDNA)特异性定量检测方法,并观察HBV cccDNA在慢性乙型肝炎患者外周血单个核细胞(PBMC)及肝组织中的分布情况。方法标本抽提核酸后,以不降解质粒的ATP依赖的DNA酶(PSAD)进行酶切,再以跨双缺口的特异性引物进行荧光PCR定量检测HBV cccDNA;用10份HBV高滴度(10~7拷贝/mL)血清和梯度稀释的HBV克隆质粒标准品,验证此检测方法的特异度和灵敏度;取慢性乙型肝炎患者PBMC和肝组织穿刺标本各50份,检测其总HBV DNA和cccDNA。结果10份血清标本均无假阳性cccDNA检测结果,灵敏度可达到10~3拷贝/mL。所有PBMC中cccDNA检测均阴性;所有肝组织中总HBV DNA和cccDNA检测均阳性,总HBV DNA含量为3．19×10~2～6．69×10~7拷贝/μg人基因组DNA,cccDNA含量为7．32×10~0～6．51×10~6拷贝/μg人基因组DNA,同一患者肝组织中总HBV DNA含量是cccDNA含量的10．7倍至9．2×10~5倍。结论本方法特异度和灵敏度高。PBMC不能支持HBV的复制。在慢性乙型肝炎患者的肝组织中均可检测到cccDNA,但其水平并非与细胞内总HBV DNA水平正相关。     

慢性乙型肝炎患者树突状细胞功能与单个核细胞乙型肝炎病毒共价闭合环状DNA的关系

目的 探讨慢性乙型肝炎(CHB)患者外周血单个核细胞(PBMC)及树突状细胞(DC)内HBV共价闭合环状DNA(HBV cccDNA)的存在状况,DC成熟度及功能状态与DC或PBMC中HBV cccDNA载量的关系.方法 分离29例CHB患者和10例健康对照者的PBMC,用重组人粒细胞-巨噬细胞集落刺激因子(GM-CS...     

实时荧光定量RT-PCR检测血清和单个核细胞中HCV RNA的意义

目的探讨实时荧光定量聚合酶链反应(FQ-RT-PCR)检测血清和外周血单个核细胞(PBMCs)中HCV RNA含量及其临床价值。方法采集可疑丙型病毒性肝炎病人血,用FQ-RT-PCR分别检测血清和PBMCs中HCV RNA含量。血清或PBMCS HCV RNA阳性者都视为HCV RNA阳性。结果检测可疑患者180例,HCV RNA阳性106例。其中血清HCV RNA阳性84例,占79.25%;PBMCs HCV RNA阳性63例,占59.43%。HCV RNA阳性比率血清高于PBMCs(χ2=9.78,P<0.01)。单独血清HCV RNA阳性43例,占40.57%;单独PBMCs HCV RNA阳性22例,占20.75%;血清和PBMCs中HCV RNA同时阳性41例,占38.68%。血清和PBMCs HCV RNA含量差异无显著性。结论同时检测血清和PBMCs HCV RNA可提高HCV感染诊断的阳性率,检测PBMCs HCV RNA对抗病毒治疗的疗效评价及治疗时间有重要意义。     

Testing for hepatitis C virus sequences in peripheral blood mononuclear cells of patients with chronic hepatitis C in the absence of serum hepatitis C virus RNA

Hepatitis C virus (HCV) is able to replicate in peripheral blood mononuclear cells (PBMC) of HCV-infected patients. Few data are available on PBMC testing for HCV RNA in serum HCV RNA negative patients, positive for anti-HCV and with histological evidence of chronic hepatitis. Twenty such patients were studied; of these, 11 were tested during interferon α (IFN) treatment, at the time of serum HCV RNA clearance and ALT normalisation: only one was found to be positive for HCV sequences in PBMC. Within 3 months of IFN withdrawal all 11 patients relapsed with high ALT and recurrence of serum HCV RNA. Of nine serum HCV RNA negative patients with chronic hepatitis C who were not receiving IFN when tested (four untreated patients and five patients who had already completed IFN schedule), PBMC HCV RNA was detected in four. Evidence of active HCV replication (presence of the minus strand genome) in PBMC was also observed in two cases. Thus, five of the 20 patients without detectable serum HCV RNA turned out to be carriers of HCV sequences in PBMC. These data indicate that: 1. PBMC are an extrahepatic replication site of HCV; this is true also in the absence of serum HCV RNA; 2. the role of PBMC as a “viral reservoir” after IFN-induced serum HCV RNA clearance is questioned; 3. the absence of both serum and PBMC HCV RNA in patients under IFN is not predictive of sustained viral loss; 4. testing for PBMC viral sequences might enhance the chances of detecting HCV infection.     

Dynamic changes of HBV DNA in serum and peripheral blood mononuclear cells of chronic hepatitis patients after lamivudine treatment

AIM: To study the dynamic changes of hepatits B virus (HBV) DNA in serum and peripheral blood mononuclear cells (PBMCs) of patients after lamivudine therapy. METHODS: A total of 72 patients with chronic HBV infection were included in this study. All patients were confirmed to have the following conditions: above 16 years of age, elevated serum alanine amonotransferase (ALT), positive hepatitis B e antigen (HBeAg), positive HBV DNA in serum and PBMCs, negative antibodies against HAV, HCV, HDV, HEV. Other possible causes of chronic liver damages, such as drugs, alcohol and autoimmune diseases were excluded. Seventy-two cases were randomly divided into lamivudine treatment group (n=42) and control group (n=30). HBV DNA was detected both in serum and in PBMCs by fluorescence quantitative polymerase chain reaction (PCR), during and after lamivudine treatment. RESULTS: In the treatment group, HBV DNA became negative both in serum and in PBNIC, of 38 and 25 out of 42 cases respectively during the 48 wk oflamivudine treatment, the negative rate was 90.5% and 59.5% respectively. In the control group, the negative rate was 23.3% and 16.7% respectively. It was statistically significant at 12, 24 and 48 wk as compared with the control group (P < 0.005). The average conversion period of HBV DNA was 6 wk (2-8 wk) in serum and 16 wk (8-24 wk) in PBMC. CONCLUSION: Lamivudine has remarkable inhibitory effects on HBV replication both in serum and in PBMCs. The inhibitory effect on HBV DNA in PBMCs is weaker than that in serum.     

慢性乙型肝炎患者树突状细胞功能与单个核细胞乙型肝炎病毒共价闭合环状DNA的关系

Objective To investigate the relationship between the maturity and function of dendritic cells (DC) and hepatitis B virus covalently closed circular DNA (HBV cccDNA) load in the peripheral blood mononuclear cells (PBMC)/monocyte-derived DC in patients with chronic hepatitis B (CHB). Methods The peripheral blood samples were collected from 29 patients with CHB and 10healthy controls. PBMC were isolated freshly and induced with granulocyte/macrophage colony stimulating factor (GM-CSF) and interleukin-4 (IL-4). A large amount of DC were harvested after seven days of culture. The expressions of CD209, CD80, CD86, human leucocyte antigen (HLA)-DR and CD1a of DC were analyzed by flow cytometry. The HBV cccDNA load in PBMC and DC were measured by real-time polymerase chain reaction (PCR). The interleukin-12 (IL-12) level in the culture supernatant of DC was determined by enzyme linked immunosorbent assay (ELISA). The effects on T lymphocyte proliferation induced by DC were tested by mixed lymphocyte reaction (MLR). The data was compared by t test and analysis of variance. Results HBV cccDNA could be detected in PBMC from 16 patients, but not in DC from all 29 patients. HBV cccDNA load was all negatively correlated with the expressions of CD209 (r= -0. 793, P＜0.01), CD80 (r= -0. 581,P＜0.05), CD86 (r=-0. 698, P＜0.01), HLA-DR (r=-0. 817, P＜0.01), CD1a (r=-0. 734, P＜0.01), IL-12 level (r=-0. 632, P＜0.05) and allogenic T lymphocyte proliferation induced by DC (r=-0. 617, P＜0.05). The expressions of CD209, CD80, CD86, CD1a and HLA-DR on DC,IL-12 level in culture supernatant of DC and the allogenic T lymphocyte proliferation induced by DC in patients with positive PBMC HBV cccDNA were all significantly lower compared to those in healthy controls, and the changes of the parameters mentioned above were greater in PBMC HBV cccDNA positive patients than those in PBMC HBV cccDNA negative patients (P ＜ 0. 05 or P ＜ 0. 01).Conclusions The function and maturity of DC are impaired in CHB patients. HBV cccDNA can be detected in PBMC from CHB patients. Moreover, the higher PBMC HBV cccDNA is, the worse DC function and maturity are, which could be one of the important mechanisms of HBV persistent infection.